InnovoTex Inc. provides a macrocycle‑mediated delivery platform that covalently links therapeutic agents to a clinically validated macrocycle scaffold, concentrating drug activity in tumor tissue while reducing systemic exposure. The modular chemistry supports diverse payloads and offers predictable pharmacokinetics and stability without relying on antibody targeting, enabling pharmaceutical and biotech firms to develop safer, more effective oncology therapies.
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many oncology drugs suffer from limited efficacy because they distribute broadly throughout the body, causing systemic toxicity and reducing the therapeutic index. Traditional antibody‑based targeting approaches can be complex, costly, and may not provide predictable pharmacokinetics, limiting their applicability for a wide range of payloads.
Solution
InnovoTex Inc. has developed a macrocycle‑mediated delivery platform that covalently links therapeutic agents to a clinically validated macrocycle scaffold. The platform concentrates drug activity within tumor tissue while minimizing systemic exposure, thereby improving the therapeutic index. Its chemistry enables predictable pharmacokinetics and stability without relying on antibody recognition, allowing rapid generation of drug conjugates for diverse payloads. The macrocycle has been used in over 1,000 patients, providing regulatory and clinical experience that de‑risks development. By offering a versatile, multi‑modal targeting system, InnovoTex aims to accelerate the creation of more effective and safer cancer therapies.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing targeted oncology therapeutics that require improved efficacy and safety profiles.
Features
- Clinically validated macrocycle scaffold with extensive human exposure data (>1,000 patients)
- Non‑antibody targeting that leverages tumor‑specific accumulation mechanisms
- Predictable pharmacokinetic profile and high chemical stability of conjugates
- Modular chemistry supporting a wide range of payloads (small molecules, toxins, radiolabels)
- Enables higher drug loading while limiting off‑target systemic exposure
- Streamlined regulatory pathway due to established safety record of the macrocycle platform